Kisqali, fulvestrant combo meets overall survival endpoint in MONALEESA-3

This article was originally published here

The late-stage trial assessed the efficacy and safety of Kisqali plus fulvestrant combination in postmenopausal women having hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or

The post Kisqali, fulvestrant combo meets overall survival endpoint in MONALEESA-3 appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply